SCHEMBL9928309

SCHEMBL9928309

CC1(C)CCN(C(=O)c2ccccc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.61
ACHE P22303 1/20 0.59
SIGMAR1 Q99720 1/20 0.58
BLM P54132 1/20 0.57
CHRM2 P08172 1/20 0.56
CHRM3 P20309 1/20 0.56
CRBN Q96SW2 1/20 0.56
ALDH1A1 P00352 3/20 0.55
TP53 P04637 1/20 0.55
CCR5 P51681 1/20 0.55
USP2 O75604 1/20 0.54
LMNA P02545 1/20 0.52
MAPK1 P28482 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4818101 0.91 CRBN (0.56) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL4818087 0.91 CRBN (0.56) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL17151131 0.86 HPGD (0.58) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL8503467 0.86 HPGD (0.58) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL9928306 0.83 BLM (0.59) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL7129676 0.82 HPGD (0.79) HPGDACHESIGMAR1BLMALDH1A1
SCHEMBL252026 0.82 HPGD (0.79) HPGDACHESIGMAR1BLMALDH1A1
SCHEMBL24304473 0.82 MGLL (0.56) HPGDALDH1A1TP53MAPK1
SCHEMBL21287275 0.82 BLM (0.54) HPGDACHESIGMAR1BLMCHRM2
SCHEMBL4813560 0.82 MAPK1 (0.61) HPGDALDH1A1TP53USP2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732029-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-9725402-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2017-08-08 US disclosed
US-20140336137-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF CARDIOXYL PHARMACEUTICALS, INC. 2014-11-13 US disclosed
US-8791134-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2014-07-29 US disclosed
US-20130045951-A1 Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2013-02-21 US disclosed
US-8318705-B2 Nitroso compounds as nitroxyl donors and methods of use thereof CARDIOXYL PHARMACEUTICALS, INC. (US) 2012-11-27 US disclosed
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE UBE INDUSTRIES, LTD. (JP) 2012-06-14 US disclosed
WO-2009137717-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF CARDIOXYL PHARMACEUTICALS INC. (US) 2009-11-12 WO disclosed
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF EVOTEC LTD. (GB) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336137-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF NOXO1, TNNI3, HAO2 HPGD 21/4885ACHE 4141/4885SIGMAR1 2050/4885
US-20090281062-A1 NOVEL NITROSO COMPOUNDS AS NITROXYL DONORS AND METHODS OF USE THEREOF NOXO1, TNNI3, HAO2 HPGD 21/4885ACHE 4141/4885SIGMAR1 2050/4885
US-20130045951-A1 Novel Nitroso Compounds as Nitroxyl Donors and Methods of Use Thereof NOXO1, TNNI3, HAO2 HPGD 21/4885ACHE 4141/4885SIGMAR1 2050/4885
US-20120149902-A1 PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE ERBB2, EGFR, FGFR1 HPGD 1864/4885ACHE 4703/4885SIGMAR1 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.